Ramosetron
Ramosetron is a potent and selective 5-HT3 serotonin receptor antagonist that blocks serotonin-mediated signals in the vagal afferents and central chemoreceptor trigger zone, preventing nausea and vomiting. It is approved in several Asian countries for the prevention of chemotherapy-induced nausea and vomiting and for the treatment of irritable bowel syndrome with diarrhea.
Peso Molecular
279,3400 g/mol
LogP
2,20
TPSA
50,70 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21
InChI
InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1
Molecular Formula
C17H17N3O
HBD / HBA
1 / 2
Ligações Rotacionáveis
2
Átomos Pesados
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Ramosetron is a potent and selective 5-HT3 serotonin receptor antagonist that blocks serotonin-mediated signals in the vagal afferents and central chemoreceptor trigger zone, preventing nausea and vomiting. It is approved in several Asian countries for the prevention of chemotherapy-induced nausea and vomiting and for the treatment of irritable bowel syndrome with diarrhea.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Ramosetron is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1643895. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 108000. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ramosetron"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ramosetron/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ramosetron/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ramosetron/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ramosetron"></drugfyi-drug>